TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05339100

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anifrolumab
Description: Participants will receive SC doses anifrolumab via AI or APFS.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Anifrolumab
Description: Participants will receive SC doses anifrolumab via AI or APFS.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Autoinjector
Description: Autoinjector will be use to administer single SC dose of anifrolumab.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Accessorized Pre-Filled Syringe
Description: Accessorized Pre-filled syringe will be use to administer single SC dose of anifrolumab.
Study: NCT06261892

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Collect HPV DNA from urine
Description: Use a sample collector to collect urine
Study: NCT05426005

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cadonilimab
Description: Cadonilimab, 6 mg/kg every 2 weeks until disease progression, intolerable toxicity, or duration of treatment for 2 years
Study: NCT05909579

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PelvicSense (R)
Description: PelvicSense® is a home-based physiotherapy program integrating multiple techniques, including relaxation, breathing, stretching, strengthening and at-home manual therapy. This program also educates participants about the anatomy and physiology of the pelvis and teaches strategies to strengthen the mind-muscle connection to the pelvis.
Study: NCT05547464

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BNT164a1
Description: Multi-antigen ribonucleic acid (RNA) vaccine for active immunization against tuberculosis administered as intramuscular injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BNT164b1
Description: Multi-antigen RNA vaccine for active immunization against tuberculosis administered as intramuscular injection

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT05885464

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BEAM-201
Description: A single dose of BEAM-201 administered by IV following one of two lymphodepletion regimens

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BEAM-201
Description: A single dose of BEAM-201 administered by IV following one of two lymphodepletion regimens
Study: NCT05434650

Intervention type: DEVICE
Intervention: electrophysiology study and ablation with an Abbott Ablation Catheter
Description: During the cardiac ablation procedure, an ablation catheter (a thin, flexible tube that can be threaded through the blood vessels to the heart) will deliver radiofrequency energy (a type of heat) to one or more areas in the upper left chamber of the heart that is causing the irregular heartbeat. The tip of the catheter will transmit energy to one or more small spots of heart tissue. This energy creates a small scar on the heart. This scar will block the electrical pathway that is causing the rapid heartbeat
Study: NCT06261229

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intermittent fasting
Description: The participant will consume food about/ within 8-hour per day

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intermittent fasting + Behavioral economic
Description: The participant will consume food about/ within 8-hour per day. They will be received a reward as money when achieve weight loss goal or/and success doing intermittent fasting 5 days/week

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intensive Lifestyle Modification
Description: Advice about nutrition knowledge, healthy eating diet, diet prescription, and exercise
Study: NCT05987371

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TQC3721 suspension for inhalation
Description: TQC3721 suspension for inhalation is a dual inhibitor targeting PDE3/4.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TQC3721 suspension for inhalation
Description: TQC3721 suspension for inhalation is a dual inhibitor targeting PDE3/4.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: TQC3721 matching placebo for inhalation
Description: Placebo without active substance.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: TQC3721 matching placebo for inhalation
Description: Placebo without active substance.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Salbutamol sulfate inhalation aerosol
Description: Salbutamol is short-acting β2 receptor agonists.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Salbutamol sulfate inhalation aerosol
Description: Salbutamol is short-acting β2 receptor agonists.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Salbutamol sulfate inhalation aerosol
Description: Salbutamol is short-acting β2 receptor agonists.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Salbutamol sulfate inhalation aerosol
Description: Salbutamol is short-acting β2 receptor agonists.
Study: NCT04751578

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: IMPEDE-FX Embolization Plug
Description: Fill an abdominal aortic aneurysm (AAA) sac outside of an endovascular aneurysm repair (EVAR) stent graft
Study: NCT06639204

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Electrical stimulation
Description: A removable appliance will be used to accelerate orthodontic tooth movement by emitting electrical stimulation.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Orthodontic treatment without acceleration
Description: No additional appliances will be used. Only the traditional fixed appliances (braces).
Study: NCT06645457

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: stress ball
Description: Patients squeeze the stress ball

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 4-7-8 breathing technique
Description: breathing in quietly through the nose for 4 seconds. holding the breath for a count of 7 seconds. exhaling forcefully through the mouth for 8 seconds.
Study: NCT06275724

Intervention type: OTHER
Intervention: inclisiran
Description: Prospective observational study. There is no treatment allocation. Patients prescribed with inclisiran are eligible to enroll into this study.
Study: NCT05146596

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: use low level light therapy,The Dr.Tai's energy cap
Description: 30 minutes each time, three times a week, a total of 12 times.
Study: NCT06148090

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: clobetasol decreasing measurement
Description: At two occasions during the clobetasol decreasing measurement at 8 AM and clinical assessment by a physician:~* Visit 1: 20-40 g clobetasol twice a week for at least 1 month~* Visit 2: 20-40 g clobetasol once a week for at least 1 month
Study: NCT05823207

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: sage essential oil
Description: It will be applied 2 times a day, at the same times, at a distance of 30 cm from the nose for 5 minutes with normal breathing and 3 drops of essential oil by placing a tampon. The PMS scale and the quality of life scale are administered to the participants at the end of the 1st, 2nd and 3rd cycles of the menstrual cycle.
Study: NCT05575414

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Didactic dietary sessions
Description: Three one-hour online nutrition group classes will be scheduled at 17, 21 and 29 weeks gestation (± 1 week). Nutrient dense foods and beverages and limiting the intake of added sugars, sodium and saturated fat will be encouraged, as well as reading the nutrition facts label, individual goal setting and self-monitoring. Physician recommended physical activity will be encouraged. Food and beverage intake data will be measured by 24-hour dietary recalls collected on three non-consecutive days. Data will be collected by telephone interview by a registered dietitian or dietary technician on four separate occasions: 16, 20 and 28 weeks gestation (± 1 week) and 36 weeks of gestation. Details on portions consumed will be estimated using standard measuring cups and household utensils. Nutrient intake will be generated using Vision Software Nutrient Analysis Software and the United States Department of Agriculture Food Composition Database, Food Data Central.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Education Tool
Description: The standard patient education tool will take the form of a leaflet which will include 1. A definition of body mass index 2. A list of measures to be taken to limit weight gain in pregnancy. 3. A description of the major nutrients required in pregnancy (folate, iron, calcium, vitamin D and protein). and 4.A description of the six food groups with recommendations for the number of servings per day.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Education Tool
Description: The standard patient education tool will take the form of a leaflet which will include 1. A definition of body mass index 2. A list of measures to be taken to limit weight gain in pregnancy. 3. A description of the major nutrients required in pregnancy (folate, iron, calcium, vitamin D and protein). and 4.A description of the six food groups with recommendations for the number of servings per day.
Study: NCT04903262

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ultraprotective ventilation with Extracorporeal CO2 removal
Description: HLS5.0 Cardiohelp® (Getinge Cardiopulmonary Care, Rastatt, Germany): 1.3 m² polymethylpentene hollow fiber membrane oxygenator. The extracorporeal blood flow is in the range of 1000 to 1500 mL/min. Sweep gas (air or oxygen) is drawn through the hollow fibers by a vacuum pump, creating a diffusion gradient for gas exchange across the membrane.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional protective ventilation
Description: Conventional lung protective mechanical ventilation, as described in the arm description (standardized ventilation)
Study: NCT05083598

Intervention type: OTHER
Intervention: 6 Minute walking test
Description: The patient is asked to repetitively walk along a 15 m track, at their best speed, in six minutes. Before and after the exercise, blood arterial pressure and dyspnea level (via Borg scale) are assessed. Cardiac frequency and peripheral Oxygen saturation are assessed before the test, and every minute and in the two minutes following the exercise.

Intervention type: OTHER
Intervention: Frailty questionaires
Description: Clinical Frailty Score, Metabolic Equivalent of Task, DUKE Activity Status Index
Study: NCT06424145

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Superior radial artery
Description: Upper radial artery, 1 ml of lidocaine

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Right side of radial artery
Description: Right side of the radial artery,1ml of lidocaine
Study: NCT05422573

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: post-test cardiovascular genetic counseling with pre-test education by video
Description: post-test cardiovascular genetic counseling with pre-test education by video

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: post-test cardiovascular genetic counseling with pre-test education by video
Description: post-test cardiovascular genetic counseling with pre-test education by video

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: required phone call with genetic counselor pre-test
Description: REQUIRED phone call with genetic counselor pre-test.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: optional phone call with genetic counselor pre-test
Description: OPTIONAL phone call with genetic counselor pre-test
Study: NCT05213390

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dora
Description: DORA uses a variety of AI technologies to deliver the patient follow-up call, including: speech transcription, natural language understanding, a machine-learning conversation model to enable contextual conversations, and speech generation. Together, these technologies cover the input, processing and analysis, and output needed to maintain a natural conversation. DORA is configured to deliver calls through a telephone connection as a real-time, stand-alone system: the operator inputs individual patient details to initiate the call and completes a summary in the electronic health record (EHR) afterwards.
Study: NCT06113237

Intervention type: DRUG
Intervention: Epidiolex
Description: Oral solution

Intervention type: DRUG
Intervention: Epidiolex
Description: Oral solution
Study: NCT06096740

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Cognitive Processing Therapy
Description: Cognitive processing therapy is a widely-utilized, empirically-supported treatment developed for PTSD. It is based on a cognitive theory of trauma which emphasizes the impact of trauma on belief systems and the development of stuck points, which are unhealthy, unrealistic, and maladaptive ways of thinking that serve to maintain unhealthy beliefs and reinforce PTSD symptoms.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Processing Therapy
Description: Cognitive processing therapy is a widely-utilized, empirically-supported treatment developed for PTSD. It is based on a cognitive theory of trauma which emphasizes the impact of trauma on belief systems and the development of stuck points, which are unhealthy, unrealistic, and maladaptive ways of thinking that serve to maintain unhealthy beliefs and reinforce PTSD symptoms.
Study: NCT05851131

Intervention type: OTHER
Intervention: Approach to Diagnosis and Treatment of Osteoporosis Questionnaire
Description: The survey will use multiple-choice questions to assess primary care physicians' knowledge on the diagnosis and treatment of osteoporosis. The questions will cover various aspects, including medication options, their mechanisms of action, side effects, and recommended vitamin D supplementation dosages. The physicians will also be asked about their sources of knowledge and how they keep themselves updated on the topic, as well as their self-evaluation of their knowledge. Background information, such as their professional and demographic characteristics, will also be collected. The survey questionnaire used in other studies will be adapted for this survey based on the Updated approach for the management of osteoporosis in Turkey: a consensus report.
Study: NCT05833581

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: New York Heart Association Classification Guide
Description: The New York Heart Association Classification Guide is a questionnaire that assists in guiding the provider in selection of the patient's class
Study: NCT05169554

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard [RC8]: rifampicin plus clarithromycin (RC) therapy for 8 weeks.
Description: Treatment will be rifampicin (600 mg, daily) and clarithromycin (500 mg, twice daily) for 8 weeks. On the posology, dosage for rifampicin and clarithromycin will be standardized according to patient body weight following WHO guidelines. In general, for a 60 kg adult dosage will be RIF, 10 mg/kg once daily and CLA, 7.5 mg/kg twice daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Investigational [RCA4]: standard (RC) plus amoxicillin/clavulanate (A) for 4 weeks.
Description: On the posology, dosage for rifampicin and clarithromycin will be standardized according to patient body weight following WHO guidelines. In general, for a 60 kg adult dosage will be RIF, 10 mg/kg once daily and CLA, 7.5 mg/kg twice daily.~Dosages for amoxicillin/clavulanate are calculated according to manufacturer indications:~Dose of amoxicillin/clavulanate 1000/125 mg twice daily, which makes a total of 2000/250 mg/day, for patients over 40 kg, and 22.5/5.6 mg/kg twice daily, which makes a total of 45/11.25 mg/kg/day, for those equal and below 40 kg. For children, posology will be adapted to the age of the patient according to drug manufacturer indications. Frequency of AMX/CLV administration will match that of CLA, twice daily.
Study: NCT04734665

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Niraparib-Bevacizumab
Description: Niraparib 200mg or 300mg (once daily\[QD\]) Bevacizumab 15mg/kg every 3 weeks (Q3W)~\*The recommended starting dosage of niraparib is 200mg QD. For patients who weigh ≥77 kg and have baseline platelet count ≥150,000/μL, the recommended starting dosage is 300 mg QD.
Study: NCT04922424

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atorvastatin
Description: Subjects will ingest placebo or ingest 20 mg atorvastatin for 30 days first. We will include 30 days of washout between treatments to minimize any potential carryover effects.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Subjects will ingest placebo or ingest 20 mg atorvastatin for 30 days first. We will include 30 days of washout between treatments to minimize any potential
Study: NCT04509180

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Catheter ablation
Description: Endovascular approach

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Convergent procedure
Description: Surgical and endovascular approach
Study: NCT04702178

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: COVAC-2
Description: Intramuscular vaccine against SARS-CoV-2

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: COVAC-2
Description: Intramuscular vaccine against SARS-CoV-2

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: COVAC-2
Description: Intramuscular vaccine against SARS-CoV-2

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: COVAC-2
Description: Intramuscular vaccine against SARS-CoV-2

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: COVAC-2
Description: Intramuscular vaccine against SARS-CoV-2

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Saline Placebo
Description: Intramuscular injection of saline placebo

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Saline Placebo
Description: Intramuscular injection of saline placebo

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Saline Placebo
Description: Intramuscular injection of saline placebo

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Saline Placebo
Description: Intramuscular injection of saline placebo

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Saline Placebo
Description: Intramuscular injection of saline placebo
Study: NCT06547944

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zanubrutinib
Description: 160mg bid/d, from C1 to CR and MRD-negative or C24

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: From C3 dose escalation, all 3 dose groups climbed from 5 mg/d to 10 mg/d, 15 mg/d, and 20 mg/d respectively, Taking 21 days of medication and 7 days of rest, 1 cycle every 28 days to CR and MRD-negative or C24

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Obinutuzumab
Description: 1000 mg C1, d1/d8/15; 1000 mg C2-6, d1
Study: NCT05319665

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Head-mounted display
Description: The intervention is a visual and auditory contact via a head-mounted display (HMD) worn by the mother airing a live video of her newborn filmed by a 2D 360° camera during and after a caesarean section. The HMD will be worn by the new mother from the moment that her newborn is moved to an adjacent room to receive the initial care until the moment when they can be reunited again. The camera will be placed in the adjacent room where the newborn, the mother's partner and a midwife will be. The camera will film the newborn and transmit the live images and the sound to the HMD worn by the mother. The mother will be able to see and hear what happens in the next room and change her angle of view by moving her head from one side to another.
Study: NCT04915352

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nasal provocation test - 725 Dermatophagoides Pteronyssinus
Description: 3 different concentrations of Nasal Provocation Test are administered to patients:~* Nasal spray at 50 SBE/ml for 36 months~* Nasal spray at 500 SBE/ml for 36 months~* Nasal spray at 5000 SBE/ml for 36 months

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Negative control
Description: Negative control using only solvent is applied in order to consider a non-specific nasal hyper reactivity.
Study: NCT05562310

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Total parenteral nutrition (TPN). This is total nutrition provided by central vein.
Description: phenylalanine, methionine and histidine intakes will be varied in the TPN solutions to study the requirements for each of these amino acids in neonates that are TPN fed.
Study: NCT05078138

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epoetin Alfa
Description: Subcutaneous injection of Epoetin Alfa 3 times per week for 4 weeks
Study: NCT05507619

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Acupuncture with Heat Therapy + Standard Care
Description: Biweekly sessions of acupuncture with heat therapy over 6 weeks (total 12 sessions), in addition to standard care (e.g. physiotherapy, dietetics, pain management).

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard Care
Description: Treatment as prescribed by orthopaedic surgeon routinely (e.g. physiotherapy, dietetics, pain management)
Study: NCT05317078

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMG 794
Description: Short-term intravenous (IV) infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMG 794
Description: Short-term intravenous (IV) infusion.
Study: NCT05416164

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Omission of radiotherapy
Description: Omission of radiotherapy
Study: NCT05575180

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acetazolamide 250Mg Tab
Description: Oral acetazolamide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methazolamide Pill
Description: Oral Methazolamide

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral placebo
Study: NCT05867576

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Acceptance and Commitment Therapy (ACT)
Description: Acceptance and commitment therapy (ACT) is an evidence-based psychological therapy that has been successfully used to improve physical and mental health among children and adults with chronic conditions. It is a third wave cognitive behavioural therapy that encourages openness to and awareness of the present moment in order to help participants maintain behaviours consistent with their life goals. ACT fosters engagement with, rather than avoidance of, painful experiences to move towards acceptance of unchangeable difficulties alongside building a rich and meaningful life despite the presence of ongoing difficulties. This gives ACT strong face validity for application to TCS patients where there can be permanent cognitive impairment and unavoidable ongoing physical symptoms and functional limitations.